Clinical Study of First-line Immunotherapy for Esophageal Cancer Published in The Lancet

 

Professor Sun, Jong Mu from the Division of Hematology-Oncology published a KEYNOTE-590 research paper as the first author and corresponding author in The Lancet (IF 79.32), an international journal, which proved the efficacy of pembrolizumab (Keytruda) as a first-line treatment for metastatic esophageal cancer.

 

In this study, 749 esophageal cancer patients around the world were randomly assigned to a group that was administered with cytotoxic chemotherapy alone and a group that was administered with a combination of cytotoxic chemotherapy and Keytruda. The results of the two groups were then compared.

 

The outcome of the study showed that there were statistically significant improvements in the overall survival for patients in the Keytruda combination treatment group. This established the superiority of the Keytruda combination treatment group in comparison to the existing standard treatment method of cytotoxic chemotherapy and is recognized to having changed the paradigm of first-line treatment for esophageal cancer.

 

Professor Sun, Jong Mu obtained the status of corresponding author as he was recognized for making decisive contributions to the successful implementation of the study by registering patients and providing high-quality research management and constructive feedback among dozens of lead researchers at individual institutions participating in this study.